
---
title: '康恩贝：拟与康臣药业在股权、营销、研发、资产业务整合方面合作'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=1082'
author: 证券时报网
comments: false
date: Fri, 07 Jan 2022 19:25:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=1082'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SS600572" style="color: #2f67d1;text-decoration: none;" code="600572" target="_blank">康恩贝</a>(600572)7日晚公告，公司与康臣药业(1681.HK)签订合作框架协议，双方拟在股权、营销、研发、资产业务整合方面合作，<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SS600572" style="color: #2f67d1;text-decoration: none;" code="600572" target="_blank">康恩贝</a>拟择机投资康臣药业股权并长期持有，并愿择机将现有和在研的慢性肾炎、肾功能不全、糖尿病肾病等项目及相关权益转让给康臣药业，康臣药业愿择机将其现有和在研的属于<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SS600572" style="color: #2f67d1;text-decoration: none;" code="600572" target="_blank">康恩贝</a>核心优势领域的项目与相关权益转让给<a class="trsHotWords" href="http://info.stcn.com/dc/stock/?stockcode=SS600572" style="color: #2f67d1;text-decoration: none;" code="600572" target="_blank">康恩贝</a>。双方将推动引进泌尿系统(主要为肾科)的创新药管线至康臣药业。</p>

                  
</div>
            